Product Information
RISEDRONATE SODIUM 35 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.5981 per EA under NDC 59762040504. Its NADAC has been published 360 times since Nov 13, 2019.
FDA first approved this application on Mar 27, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30.1; 4.9 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762040504
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RISEDRONATE SODIUM HEMIPENTAHYDRATE; RISEDRONATE SODIUM MONOHYDRATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA020835FDA Approved
3/27/1998
TE Code
AB
On Market Since
5/17/2002
Pharmacological Classes
Price Statistics
The NADAC for RISEDRONATE SODIUM 35 MG TABLET has been published 360 times since Nov 13, 2019, and over the history we have for it it has declined 72.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5981 per EA |
|---|---|
| All-time high | $5.8238 (Nov 13, 2019) |
| All-time low | $1.1853 (Sep 20, 2023) |
| 52-week high | $2.4340 |
| 52-week low | $1.5981 |
| Median price | $2.4030 |
| Average price | $2.9153 |
| Largest weekly change | +76.8% (Dec 20, 2023) |
| Weeks tracked | 360 |
| Tracking since | Nov 13, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Risedronate Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RISEDRONATE SODIUM 35 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RISEDRONATE SODIUM 35 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $1.5981 per EA (NDC 59762040504), effective Sep 30, 2026.
How has the price of RISEDRONATE SODIUM 35 MG TABLET changed over time?
Over the history we have for it, the NADAC for RISEDRONATE SODIUM 35 MG TABLET has declined 72.6%. It has been tracked across 360 weekly CMS publications since Nov 13, 2019.
What are the highest and lowest recorded NADAC prices for RISEDRONATE SODIUM 35 MG TABLET?
Since Nov 13, 2019, the NADAC for RISEDRONATE SODIUM 35 MG TABLET has ranged from a low of $1.1853 (Sep 20, 2023) to a high of $5.8238 (Nov 13, 2019), with a median of $2.4030 per EA.
Are there cheaper alternatives to RISEDRONATE SODIUM 35 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as RISEDRONATE SODIUM 35 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures RISEDRONATE SODIUM 35 MG TABLET?
RISEDRONATE SODIUM 35 MG TABLET (NDC 59762040504) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.